Trefoil factor family (TFF) peptides have been shown to play a pivotal role in oncogenic transformation, tumorigenesis and metastasis by changing cell proliferation, apoptosis, migration and invasion behavior of various cancer cell lines. In the study presented, we investigated the effect of TFF1 overexpression on cell growth, viability, migration and tumorigenicity of different retinoblastoma (RB) cell lines. Transient TFF1 overexpression significantly increases RB cell apoptosis levels. Stable, lentiviral TFF1 overexpression likewise decreases RB cell viability, proliferation and growth and significantly increases apoptosis as revealed by WST-1 assays, BrdU and DAPI cell counts. TFF1-induced apoptosis is executed via cleaved caspase-3 activation as revealed by caspase blockage experiments and caspase-3 immunocytochemistry. Results from pG13-luciferase reporter assays and Western blot analyses indicate that TFF1-induced apoptosis is mediated through transcriptional activity of p53 with concurrently downregulated miR-18a expression. In ovo chicken chorioallantoic membrane (CAM) assays revealed that TFF1 overexpression significantly decreases the size of tumors forming from Y79 and RB355 cells and reduces the migration potential of RB355 cells. Differentially expressed genes and pathways involved in cancer progression were identified after TFF1 overexpression in Y79 cells by gene expression array analysis, underlining the effects on reduced tumorigenicity. TFF1 knockdown in RBL30 cells revealed caspase-3/7-independent apoptosis induction, but no changes on cell proliferation level. In summary, the in vitro and in vivo data demonstrate for the first time a tumor suppressor function of TFF1 in RB cells which is at least partly mediated by p53 activation and miR-18a downregulation.
RB is the most common primary intraocular malignant tumor in young children with an incidence of one out of 15,000-20,000 livebirth. 1 The molecular pathogenesis of RB was intensively investigated during the last decades and is proposed to be a multistep process of progression from normal retinal toward RB cells. 2 TFFs peptides are aberrantly expressed in a wide range of human tumors and tumor cell lines, e.g., gastric, breast and ovarian cancer and retinoblastoma cells (for review see Ref.
3). Three members (TFF1, TFF2 and TFF3) of small secreted proteins of the TFF family have been characterized in mammals so far. They possess a clover leaf-like disulfide structure so-called TFF domain. TFFs are mainly expressed in the gastrointestinal tract and have been reported to be key players in the maintenance and protection of epithelial surfaces. 4 Additionally, TFFs are expressed in the central nervous system, in ocular tissues and in the murine retina (for review see Ref. 3) . Previous studies by our group revealed that only TFF3, but not TFF1 is expressed in the healthy human retina, 5 whereby RB cell lines exhibit high levels of TFF1.
5,6
The function of TFF1 in cancer development and progression was described in a context-dependent manner as oncogenic or tumor suppressive. 7 The loss of TFF1 in gastric cancer and its overexpression in ovarian cancer promote tumorigenesis involving the Wnt/ß-catenin signaling pathway. 8 Loss of TFF1 expression is epigenetically regulated by promotor methylation in gastric cancer 9 and likewise in retinoblastoma cell lines as recently published by our group. 6 The mechanisms by which TFF1 promotes apoptosis and changes proliferation behavior of tumor cells remain, however, largely unknown. Recently, Soutto et al. showed that TFF1 activates p53 via downregulation of microRNA (miR) miR-504 in gastric cancer cell lines. 10 The activated tumor suppressor p53 itself is able to induce apoptosis and cell cycle arrest. 11 However, the role of TFF1 in tumorigenesis in general and the mechanisms by which TFF1 regulates tumorigenesis in retinoblastoma cells in particular have not been investigated so far. In the study presented, we showed that deregulation of TFF1 not only induces apoptosis but also decreases proliferation and tumor growth of RB cell lines in a p53-and caspase-dependent manner with implicated miRNA regulation.
Material and Methods

Cell culture
The human retinoblastoma cell lines Y79, 12 originally purchased from the Leibniz Institute DSMZ (German Collection of Microorganisms and Cell Cultures), RBL30, established and first described by Griegel et al. 13 and formerly donated by K.
Heise as well as the cell line RB355 were kindly provided by H.
Stephan. All RB cell lines were last tested and authenticated in September 2015. Mutation analyses were conducted using a MLPA Kit (MRC-Holland, Amsterdam, The Netherlands; Salsa MLPA Kit P047 RB1) and additional sequencing of the RB1 gene was performed. Besides, STR analyses confirmed the authenticity of the cell lines. The cell lines were cultivated as suspension cultures as described previously. 14 Human embryonic kidney cells (HEK293-T) were grown as adherent cell culture in Dulbecco's modified Eagle's medium (DMEM; PAN-Biotech, Aidenbach, Germany) with 10% fetal bovine serum (FBS; PAN-Biotech, Aidenbach, Germany), 4mM Lglutamine (Gibco, Germany), 100 U penicillin/ml and 100mg streptomycin/ml (Gibco, Germany) at 378C, 5% CO 2 and 95% humidity.
Plasmids and lentiviral expression vectors
For the pLVX-IRES-Neo_TFF1 plasmid, the human TFF1 cDNA sequence was polymerase chain reaction (PCR) amplified from human stomach by RT-PCR using the forward primer 5 0 -GGTCGAATTCGGAGCAGAGAGGAGGCAATG-3 0 and reverse primer 5
0 -AGT CCTCGAGGGCAGATCCCTGCAGAAGTG-3 0 containing EcoRI and XhoI restriction sites (underlined). After digestion with EcoRI/XhoI the TFF1 PCR product was ligated into the pLVX-IRES-Neo vector (Clontech, Saint-Germain-enLaye, France), digested with the same restriction enzymes. For the generation of a TFF1 expression vector under the control of the ubiquitin C promoter (pCS21_UBQ_TFF1), the human TFF1 cDNA sequence was excised by digestion with SalII/ BamHI and ligated into the pCS21_UBQ vector (for details see Ref. 15) , digested with the same restriction enzymes.
To generate a lentiviral TFF1 expression vector (pLenti CMV_TFF1), the human TFF1 cDNA sequence was cut out of the pLVX-IRES-Neo_TFF1 vector by the use of EcoRI and XhoI and ligated into the pENTR4 vector, digested with the same restriction enzymes. TFF1 was finally cloned into the pLenti CMV Puro Dest vector (Addgene, Cambridge, USA) by the use of a Gateway LR Clonase II Enzyme Mix (Invitrogen, Karlsruhe, Germany), following the manufacturers protocol. All vector constructs were verified by sequencing.
The "Mission shRNA Plasmid DNA" with a pLKO.1-puro backbone used in the TFF1 knockdown experiments was purchased from Sigma-Aldrich (shTFF1 clone TRCN000033614) and the nonmammalian shRNA control pPRIME-CMV-Neo-FF3 (p234) containing a targeting hairpin sequence against firefly-luciferase was used in all transduction experiments.
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TFF1 overexpression and TFF1 knockdown in retinoblastoma cell lines For transient TFF1 overexpression, Y79 RB cells were transfected as previously described by our group in Ref. 15 . Instead of the pCS21_UBQ_TFF3 the pCS21_UBQ_TFF1 vector was used for transfection.
As described previously, 14 for virus production, HEK293T cells were transfected with each of the following plasmid DNAs: packaging vector pczVSV-G, 17 pCD NL-BH 17 and either pLenti CMV_TFF1, pPRIME-CMV-Neo-FF3 (p234) or shTFF1 clone. For stable TFF1 overexpression or TFF1 knockdown, GFP-labeled Y79, RB355 and RBL30 RB cell lines were used, generated as described previously.
14 For lentiviral transductions, the experimental procedure used was the same as
What's new?
The role of TFF1 in cancer progression has been extensively described in the literature, with TFF1 being considered as a tumor suppressor gene or a potential oncogenic factor depending on the context. The role of TFF1 in retinoblastoma tumorigenesis and underlying mechanisms, however, remain unknown. Here, the authors show that deregulation of TFF1 induces apoptosis and decreases proliferation and tumor growth of human retinoblastoma cell lines in a p53-and caspase-dependent manner with implicated miR-18a regulation. Altogether, the in vitro and in vivo data depict for the first time a tumor suppressor function of TFF1 in retinoblastoma.
previously described, 15 but instead of TFF3-coding lentiviral particles, TFF1-or shTFF1-coding particles were used.
RNA extraction, gene expression analysis and quantitative real-time PCR
RNA isolations from RB cell lines and CAM tissue were performed using the NucleoSpin RNA II kit (Macherey and Nagel, D€ uren, Germany), the miRNeasy Kit (Qiagen, Hilden, Germany) and the miRNeasy FFPE Kit (Qiagen, Hilden, Germany), respectively.
Labeling of total RNA in the two-color format for gene expression analysis was performed as described by the manufacturer (Agilent Technologies, D€ usseldorf, Germany). The cRNA was hybridized to 43 44 K "Whole Human Genome Oligo Microarrays" (Agilent, V2, D€ usseldorf; Germany) and "Spike-In positive controls" (Agilent, D€ usseldorf; Germany) were added as internal controls. Expression arrays were scanned (Agilent Technologies Scanner G2505C, D€ usseldorf, Germany) and quantified using the Agilent Feature Extraction V10.7.1.1 Software.
For quantitative real-time PCR analyses cDNA was synthesized with the QuantiTect Reverse Transcription Kit (Qiagen, Hilden, Germany) following the manufacturers protocol and the following human Taqman Gene Expression Assays (Applied Biosystems, Dreieich, Germany) were used: TFF1 (Hs00907239 m1),
, GAPDH (Hs99999905_m1) and 18S (Hs99999901_s1). The latter was used as an endogenous control for human and chicken samples. Using the TaqMan Universal PCR Master Mix (Applied Biosystems, Dreieich, Germany), real-time PCR reactions were performed in duplicate and a total volume of 20 ml was applied to the following program: 2 min at 508C, 10 min at 958C, 40 cycles of 15 sec at 958C and 60 sec at 608C.
For miRNA analyses cDNA was synthesized and quantitative real-time PCR analyses were performed using the miScript PCR Starter Kit (#2181193; Qiagen, Hilden, Germany) as described by the manufacturer. The "miScript HiSpec Buffer" for quantification of mature miRNA was used with specific primers for miR-504 5p (5
as endogenous control. The reactions were performed in duplicates using a 7300 real-time PCR system (Applied Biosystems, Dreieich, Germany).
Western blotting and immunofluorescence staining
After washing in PBS, total protein was lyzed for 60 min at 48C in radioimmunoprecipitation assay (RIPA) buffer plus additives 5 and cleared by a 10 min centrifugation step at 14,000 rpm (48C). Equal amounts of protein extracts were separated by 12% SDS-PAGE and transferred onto nitrocellulose membranes. The following primary and secondary antibodies were used: TFF1 (1:1,000): ERP3972, (Abcam, Cambridge, UK); p53 (1:400): sc-71817, (Santa Cruz, Heidelberg, Germany); ß-actin (1:1,000): #4967, (Cell Signaling, Leiden, The Netherlands); HRP-conjugated goatanti-rabbit or rabbit-anti-mouse antibody (1:10,000): P0448 and P0260; (DAKO, D€ usseldorf, Germany). Signals were developed by the Western Lightning Chemiluminescence Reagent Plus-ECL (Perkin Elmer, Rodgau, Germany).
For immunofluorescence staining, 1 3 10 5 cells were seeded on poly-D-lysine (Sigma, Hamburg, Germany) coated coverslips. Cells were fixed with 4% paraformaldehyde (PFA; Sigma-Aldrich, Hamburg, Germany) for 1 hr at 48C, washed three times with phosphate buffered saline (PBS; pH 7.4) and permeabilized with 100% methanol for 5 min on ice. Cells and 10 mm cryo-sections from tumor tissue were blocked with PBS containing 0.3% Triton X-100 (Sigma, Hamburg, Germany), 4% bovine serum albumin (BSA; Roth, Karlsruhe, Germany) and 5% normal goat serum (NGS; Dako, D€ usseldorf; Germany) for 1 hr at room temperature. The following primary antibodies were used: TFF1 (1:200): NCL pS2, (Novo Castra, Wetzlar, Germany); cleaved caspase-3 (1:400): #9664 5A1E, (Cell Signaling, Leiden, The Netherlands); cleaved caspase-7 (1:1600): #8438, (Cell Signaling, Leiden, The Netherlands); antinuclei clone 235-1 (1:100): MAB1281, (Merck Millipore, Darmstatd, Germany) diluted in PBS with 0.1% Triton X-100, 4% BSA and 1% NGS. A goat anti-rabbit or anti-mouse antibody labelled with Alexa Fluor 488 or 594 (Molecular Probes, Darmstatd, Germany), diluted 1:1,000 in PBS with 1% BSA was used to visualize the reaction. As controls, in all cases PBS was substituted for the primary antisera in order to test for nonspecific labeling.
Cell viability
To determine cell viability, 4 3 10 4 cells in 100 ml medium were seeded in two triplicates in a 96-well plate. Afterward, 10 ml of a water soluble tetrazolium-1 (WST-1) salt solution was added to each well and the cells were incubated at 378C for different time points. Quantification of the formazan dye produced by viable cells was performed by measuring the absorbance at 450 nm in a microplate reader.
Growth kinetic
To determine growth kinetics, 3 3 10 5 cells were seeded in 500 ml DMEM with supplements in a 24-well plate and vital cells were counted manually using the trypan blue exclusion method. Cells were seeded in triplicates and counted every 24 hr over a time period of 1 week.
Cell proliferation and apoptosis detection
Cell proliferation was determined by 5-Bromo-2 0 -deoxyuridine (BrdU; Sigma, Hamburg, Germany) incorporation. For BrdU immunocytochemistry 5 mM BrdU was added to the cells 4 hr prior to PFA fixation. Cells were incubated with a rat anti-BrdU antibody (1:1,000; ab6326; Abcam, Cambridge, UK) and proliferating cells were visualized using a goat antirat antibody labeled with Alexa Fluor 594 (1:1,000; Molecular Probes, Darmstadt, Germany).
In order to determine changes in apoptosis levels, cells were stained with 4 0 ,6-Diamidino-2-phenylindole (DAPI; Sigma, Hamburg, Germany) and pycnotic nuclei were counted manually.
For each experiment six coverslips were stained and the percentages of proliferating or apoptotic cells were calculated as described previously by our group. 14 
Caspase-dependent apoptosis
In order to inhibit endogenous caspase activity, the broadspectrum caspase inhibitor Boc-D-Fmk (Calbiochem, Darmstadt, Germany) was used. Cells were seeded on poly-Dlysine coated coverslips as described before and were cultured in the presence of 50 mM of Boc-D-Fmk for 24 hr. Afterward cells were fixed with 4% PFA and DAPI-stained to determine the number of pycnotic nuclei.
CAM assay
In order to test for changes in tumor formation and migration capacity, TFF1 overexpressing, GFP-labeled RB cells and control cells were grafted on the CAM or injected into the allantoic vein of chicken embryos as described previously. 14, 18 To boost the effect of stable TFF1 overexpression in the grafted cells, every second day 50 ml supernatant from Y79 RB cell cultures transiently overexpressing TFF1 was applied to the graft area. For each RB cell line, 20 eggs were grafted or intravenously injected in at least three independent experiments.
Harvesting of tissue
Seven days after grafting (E10-17) tumors which formed from the grafted cells were excised, measured, photographed and (i) shock frozen for quantitative real-time PCR or (ii) cryo-embedded as described in Ref. 15 . Six days after injection (E12-E18) tissue punches of each ventral "lower CAM" were isolated for scanning GFP-positive RB cells by fluorescence microscopy and cryoconserved for RNA extraction. 14 
Luciferase assay
TFF1-dependent p53 activity was measured with the p53 responsive reporter pG13-Luc (with p53 binding site) and the nonresponsive reporter pG15-Luc (with a mutant p53 binding site; Addgene, Cambridge, USA 19 ) after cotransfection of pCS21_UBQ_TFF1 or an empty control vector (pCS21_UBQ). As controls, cells were transfected with a promotorless pGL3-basic and a pGL3-control luciferase vector containing an SV40 promotor and enhancer. All cells were additionally cotransfected with pGL4.75 (Renilla-Luc) for normalization. Cells were lyzed after 48 hr in 13 Passive-Lyse Buffer (Promega, Mannheim, Germany) and the luciferaseactivity was measured with the "Dual Luciferase reporter assay system" (E1910; Promega, Mannheim, Germany) as described by the manufacturer. The relative p53 luciferase-activity was determined as the quotient of firefly-luciferase and renilla-luciferase-activity. The analysis was performed in triplicate.
Statistical analysis
All assays were performed in triplicate. Statistical analyses were performed using GraphPad Prism 6. Data represent means 6 SEM of three independent experiments from independent RB cell cultures. Results were analyzed by a Student's t test or oneway ANOVA and Newman-Keuls posttest and considered significantly different if *p < 0.05, **p < 0.01 or ***p < 0.001. Statistics on the growth curves was performed using a free web interface http://bioinf.wehi.edu.au/software/compareCurves/, which uses the compareGrowthCurves function from a Statistical Modeling package called statmod, available from the R Project for Statistical Computing: http://wwww.r-project.org, previously described elsewhere. 20 For statistical analysis and search for differentially expressed genes of the Whole Human Genome Oligo Microarray data the software package LIMMA (R-library, Bioconductor, http://www.R-project.org) was used. To identify involved biologic pathways and perform gene ontology (GO) term analysis of the target genes, the Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analysis was conducted with the database for annotation, visualization and integration discovery (DAVID) software, 21 based on the hypergeometric distribution. p < 0.05 was set as threshold for selection of pathways and GO terms.
Results
TFF1 overexpression induces apoptosis and inhibits growth in RB cell lines
To analyze the effect of TFF1 overexpression in human RB cell lines, we first transiently transfected Y79 cells with a TFF1 expression vector. TFF1 overexpression was confirmed by real-time PCR (data not shown), Western blot (Fig. 1a) and immunofluorescence staining, the latter revealing a cytoplasmatic localization of TFF1 (Fig. 1b) . Quantification of apoptosis levels by DAPI cell counts indicated a highly significant induction of apoptosis in TFF1 overexpressing Y79 cells as compared to control cells (Fig. 1c) . Next, we generated Y79 and RB355 cells, stably overexpressing TFF1 and performed WST-1 cell viability assays. Both TFF1 overexpressing cell lines exhibited a significant reduction in cell viability (Fig. 2a) and displayed significantly inhibited growth as revealed by BrdU cell counts (Fig. 2b ) and growth curve analyses (Fig. 2c) . Besides, after TFF1 overexpression a significant increase in apoptosis levels was detectable (Fig. 2d) .
TFF1 activates the p53/caspase-pathway axis with involvement of miRs
To investigate whether TFF1-mediated apoptosis induction is caspase-dependent, we treated TFF1 overexpressing RB cell lines with the broad spectrum caspase inhibitor Boc-D-Fmk. Compared to cell death levels after TFF1 overexpression alone, apoptosis was significantly reduced in both RB cell lines after Boc-D-Fmk treatment, indicating the involvement of caspases in TFF1-mediated apoptosis. By contrast, endogenous apoptosis seems to be mostly caspase-independent since the number of pycnotic nuclei was not significantly reduced by Boc-D-Fmk treatment (Fig. 2d) . The involvement of caspases was confirmed by immunofluorescence staining using an antibody detecting the cleaved and thereby activated form of the executioner caspase-3 (Fig. 2e) . Cell counts from cleaved caspase-3 stains revealed that TFF1 overexpression significantly increases caspase-3 levels in Y79 and RB355 cells as compared to control cells (Fig. 2e) .
Soutto et al. 10 recently showed that TFF1 activates p53 via downregulation of miR-504 in two gastric epithelial cell lines. To determine whether this signaling cascade also applies for RB cell lines, we first analyzed the transcriptional activity of p53 by luciferase reporter assay. Therefore, Y79 and RB355 were transiently cotransfected with pG13-Luc along with TFF1. Compared to control cells the relative luciferase-activity of the p53 responsive reporter was significantly increased in TFF1 overexpressing cells (Figs. 3a and 3b) . Besides, Western blot analyses revealed an increase in p53 expression in TFF1 overexpressing Y79 and RB355 cells (Figs. 3c and 3d) , whereas p53 mRNA expression was not concomitantly upregulated (data not shown).
The microRNAs miR-504, 22 miR125b, 23 miR-18a 24 and miR-18b 25 are discussed to regulate protein levels and function of p53. Therefore, we next analyzed the expression of these miRs in response to TFF1 overexpression in both RB cell lines. Quantitative real-time PCR analysis revealed that miR-504 is not expressed in the RB cell lines investigated (data not shown). We, however, detected significantly decreased levels of miR-18a expression in Y79 cells after TFF1 overexpression. In RB355 cells miR-18a level likewise seemed to be reduced, but this decrease did not reach significance (Fig. 3e) . Expression levels of miR-125b and miR-18b were not significantly changed in both cell lines investigated (Fig. 3e) . Gene expression analyses of miR-18a and miR-18b in 13 primary RB tumor samples revealed significantly increased levels of expression compared to a human retina control pool, further suggesting the putative involvement of these miRs in RB tumor formation (supporting information Fig. S1 ).
TFF1-dependent gene regulation in Y79 RB cells
To gain a deeper insight into the molecular function of TFF1 in RB cells, we analyzed and compared gene expression profiles of TFF1 overexpressing Y79 and control cells using whole genome microarrays. To identify TFF1 responsive genes, the mean of two biological replicates was determined and corresponding genes were selected (p < 0.05). A 1.5-fold change (FC) relative to the control and an expression level reflected by a minimal fluorescence intensity of 150 were used as criteria for a TFF1 responsive gene selection (RGS) cut off. We performed pathway enrichment analysis with RGS to identify related gene functions. DAVID analyses of GenBank accession numbers of 242 differentially expressed genes filtered as RGS revealed four KEGG pathways and 54 GO terms with p < 0.05 as shown in supporting information Table S1 . Three identified KEGG pathways were associated with cancer ("bladder cancer, "melanoma" and "pancreatic cancer"), all with involvement of the MAPK/ERK pathway, Cyclin D1-mediated cell cycle control and p53 signaling. Some of the highly significant related GO terms were "response to hypoxia" and "response to oxygen levels" (p < 0.001) and several terms associated with angiogenesis ("blood vessel development," "angiogenesis," "vascular development" and "blood vessel morphogenesis"), as well as "cell migration," "cell motility" and "regulation of cell proliferation" were identified. In a functional annotation clustering analysis angiogenesis-and migration-related genes were likewise among the highest enrichment scores. In order to create a list of the highest significant differentially expressed genes, we reanalyzed our RGS and subsequently filtered only genes with the same expression changes (at least p < 0.05, 1.5 FC and fluorescence intensity of 150) in both biological replicates. Thereupon, the number of genes significantly regulated after TFF1 overexpression was reduced to five upregulated and 11 downregulated genes (Table 1 ). Microarray data were validated for selected genes by quantitative real-time PCR, confirming that TFF1 overexpression causes a significant increase in CDKN1C (p57) expression as well as an upregulation of GIPR and MAGI2 expression levels, which, however, did not reach significance (supporting information Fig. S2 ). Besides, a slightly yet not The indicated intensity ratios of p53 protein levels relative to ß-actin levels were calculated using Multi Gauge V3.0 software. (e) As revealed by real-time PCR, expression levels of several p53 related micro RNAs (miRs) were regulated after TFF1 overexpression, however, only changes in miR-18a expression in Y79 cells reached significance. Values are means from at least three independent experiments 6 SEM. *p < 0.05; **p < 0.01 statistical differences compared to the control group calculated by Student's t test.
significantly decreased expression of PTPRU and HS3ST3A1 could be detected following TFF1 overexpression (supporting information Fig. S2 ). Our microarray gene expression data indicate that TFF1 overexpression in Y79 RB cells lead to several gene expression changes in different biological systems, which are potentially connected to tumor development and progression. Additionally, some of the highly significant regulated genes may be functionally involved in TFF1-mediated effects on apoptosis and cell growth and therefore involved in RB tumor progression.
TFF1 overexpression reduces size of tumors formed by RB cells in ovo
Soft agarose assays, a model to test for changes in anchorageindependent growth, indicated that the colony formation capacity of Y79 or RB355 cells did not significantly change following TFF1 overexpression (data not shown).
To investigate whether TFF1 influences RB cell tumor growth and migration capacity, we used the chicken CAM as an in vivo model. Stably TFF1 overexpressing Y79 or RB355 cells were inoculated onto the CAM of 10-day-old chicken embryos. Measurements of the tumors developing from inoculated Y79 and RB355 cells (Figs. 4a and 4b ) revealed that TFF1 overexpressing RB cells develop significantly smaller tumors than control cells. There was no significant change in the number of developing tumors between TFF1 overexpressing cells and control cells (data not shown). As shown by tumor cryosections stained with H&E, inoculated GFP-positive Y79 and RB355 cells invaded into the CAM tissue and formed tumors in the mesodermal layer or between the outer ectodermal and mesodermal layer (Figs. 4df) .
Migration capacity was investigated by injecting stably TFF1 expressing Y79 or RB355 cells into a CAM vein of 12-day-old chicken embryos. As revealed by quantitative realtime analysis, significantly fewer TFF1 overexpressing RB355 cells than control cells were detectable in the lower part of the CAM tissue, indicating a lower migration capacity of TFF1 overexpressing RB355 cells (Fig. 4c) . For Y79 cells, only few GFP positive cells were detectable in lower CAM punches, indicating that the number of migrating cells were below the detection limit (data not shown).
TFF1 knockdown induces caspase-3/7-independent apoptosis in RBL30 cells
We performed TFF1 knockdown (KD) experiments in the RB cell line RBL30, exhibiting decently detectable endogenous TFF1 levels, 6 to confirm TFF1 effects on growth and apoptosis. Testing different TFF1-specific shRNA clones, we achieved a very efficient knockdown with an 80-95% reduction in TFF1 expression confirmed by quantitative Real-time PCR (data not shown). Besides, the efficiency of the KD was verified on protein level by Western blot (Fig. 5a ). In RBL30 cells we did not detect any changes in proliferation levels after TFF1 KD (data not shown). Surprisingly, in RBL30 cells apoptosis remained induced after TFF1 KD (supporting information Fig. S3 ) and TFF1-mediated apoptosis induction was likewise caspase-dependent (Fig. 5b) . However, in contrast to apoptosis induction in TFF1 overexpressing RB cells the KD effect on apoptosis levels is not caspase-3 and also not caspase-7-dependent in this cell line (data not shown).
Discussion
The role of TFF1 in cancer progression has been extensively described in the literature. Depending on the context, TFF1 is considered as a tumor suppressor gene or potential oncogenic factor involved in multiple tumor formation pathways. 7 In breast cancer TFF1 overexpression leads to a reduction of tumor development, indicating a tumor suppressive role of TFF1. 26 By contrast, more than half of gastric cancer tumors lose TFF1 expression by different genetic alterations 27, 28 and loss of TFF1 promotes gastric dysplasia as well as adenocarcinoma in a mouse model. 10, 29, 30 The role of TFF1 in retinoblastoma progression remained, however, still unclear. Thus, in the study presented, we set out to investigate the mechanisms of potentially tumor suppressive TFF1 effects in RB progression. In a previous study by our group we demonstrated that high TFF1 expression correlates with low growth kinetics in RB cell lines. 5 In the present we examined whether TFF1 overexpression exerts growth repressing effects in RB cell lines. Our data confirmed that forced TFF1 induces lower RB cell viability, resulting in decreased proliferation rates and increased apoptosis in Y79 and RB355 cell lines. In line with our results, TFF1 inhibits growth and increases apoptosis in gastric cancer cells. 31, 32 Our inhibitor studies revealed that TFF1-induced apoptosis is caspase-dependent and mediated by activation of executioner caspase-3 in both RB cell lines investigated, as previously described for gastrointestinal cells. 33 Soutto et al. recently published that TFF1 activates p53 through down-regulation of miR-504 in gastric cancer cells, in turn leading to a reduction of the tumorigenic potential of these cells. 10 We hypothesized that p53 activation by TFF1 might also be required for the reduction of the tumorigenic potential in RB cells and this indeed proved to be the case. Following TFF1 overexpression we found transcriptional p53 activity and increased protein expression, but p53 mRNA levels remained unaffected. Thus, a transcriptional upregulation of p53, frequently observed in response to oncogenic activation, 34 had to be excluded as a molecular mechanism. We speculated that TFF1 might affect p53 function and protein levels through regulation of miRs. Different miRs have been reported to be involved in p53 activation including miR-504, 10, 22 miR-125b, 23 miR-18b 25 and miR-18a. 24 Micro RNA18a has been reported to modulate p53 expression by directly targeting interferon regulatory factor 2 (IRF2), while decreased miR-18a expression causes reduced cell proliferation, migration and invasion of gastric cancer cells. 24 Micro RNA-18a, encoded by the miR-17-92 cluster, was also found to be upregulated in many other cancers, including glioblastoma 35 and retinoblastoma. 36 Nittner et al. demonstrated that in mice as well as in the human retinoblastoma cell lines RBL15, WERI-Rb1 and Y79 overexpression of the miR-17-92 cluster is required for the formation of aggressive and invasive retinoblastoma. 37 The oncogenic miR-17-92 cluster is negatively regulated by p53 38 and transcriptionally upregulated via E2F proteins, activated following RB1 inactivation. Deregulation of the p53/RB pathway, frequently found in retinoblastoma development, may result in overexpression of the miR-17-92 cluster. 37 Coinactivation of miR-17-92, RB1 and p53 leads to synthetic lethality of retinoblastoma cells, suggesting that miRNAs of the miR-17-92 cluster provide an interesting target for alternative therapeutic approaches. 37 Our study confirmed high miR-18a expression in RB cell lines as well as in 13 primary RB tumors. Interestingly, miR18a expression was significantly downregulated after TFF1 overexpression in Y79 cells and decreased in RB355 cells. Therefore, TFF1 might represent a regulator of miR-18a expression, which could in turn modulate p53 by targeting IRF2. 24 Alternatively, miRNA-18a might be downregulated upon upregulation of p53, which acts as a negative regulator of the miR-17-92 cluster. 38 Other miRNAs implicated in p53 regulation were either not expressed in the RB cells investigated in our study (miR-504) or not significantly regulated after forced TFF1 expression (miR-125b and miR-18b). It will be necessary to further investigate the interaction between TFF1, miR-18a and p53 activation to fully understand the role of TFF1 in RB tumor formation.
Next to the regulation of miRs, TFF1 overexpression in Y79 cells also induced changes in gene regulation as revealed by gene expression array analysis. GO-term analysis and functional annotation clustering of genes differentially regulated after TFF1 overexpression revealed several general connections to tumor development and progression, such as groups of migration-related genes. These data are in line with results of our in vivo CAM experiments clearly demonstrating significantly reduced tumor sizes following forced TFF1 expression in both cell lines investigated as well as a significantly decreased migration potential of RB355 cells. These effects could at least partially be mediated through differentially regulated genes involved in migration processes. Some of the highest significant related GO terms were "response to (1) and absence (-) of a broad spectrum caspase inhibitor (Boc-D-fmk; gray bars) showed that the proapoptotic effect of TFF1 knockdown is at least partially caspase-dependent. Values are means of at least three independent experiments 6 SEM. **p < 0.01; ***p < 0.001 statistical differences compared to the control group calculated by one-way ANOVA and Newman-Keuls posttest. [Color figure can be viewed at wileyonlinelibrary.com] hypoxia" and "response of oxygen levels." Previous studies demonstrated that hypoxia stimulation of Y79 cells increases cell invasion and migration ability via NF-jB signaling. 39 Tumor protein p53-mediated repression of the already discussed miR-17-92 cluster likewise has a crucial function in hypoxia-induced apoptosis in colon cancer cell lines. 38 Cyclin-dependent kinase inhibitor 1C (CDKN1C or p57) , one of the genes differentially upregulated after TFF1 overexpression, encodes a potent tight-binding inhibitor of several G1 cyclin/Cdk complexes and a negative regulator of cell proliferation. 40 Thus, upregulated CDKN1C and concordantly downregulated cyclin D1 levels, potentially resulting in altered cell cycle progression, could explain decreased RB cell growth rates after TFF1 overexpression. Besides, inducible expression of CDKN1C inhibits motility and invasion of glioma cells. 41 Another gene upregulated after TFF1 overexpression is MAGI-2 (also known as S-SCAM), encoding a multidomain scaffolding protein highly expressed in the brain 42 and localized at epithelial junctions playing a role in neuronal cell-cell contact. 43 MAGI-2 has been reported to inhibit cell migration and proliferation in human hepatocarcinoma cells, 44 which could possibly also explain the decreased proliferation potential of RB cells after TFF1 overexpression.
The gastric inhibitory polypeptide receptor gene (GIPR), normally expressed in neuroendocrine tissues and brain, 45 is also upregulated following TFF1 overexpression. GIPR is also expressed in colorectal cancer where increased proliferation and activation of mitogen-activated protein kinase could be detected after receptor activation. 46 Interestingly, TFF1 overexpression is also associated with aggressive colorectal cancer formation. 47 Keeping in mind that no TFF1 receptor is identified so far the regulation of GIPR could be an interesting starting point for further experiments.
Some of the genes downregulated after TFF1 overexpression are involved in cancer progression like HS3ST3A1, which is expressed in lung cancer cells with high metastatic potential 48 or the tumor suppressor gene PTPRU. PTPRU expression is required for glioma growth and motility 49 and PTPRU knockdown leads to reduced cell growth, migration, invasion and adhesion of gastric cancer cells. 50 In conclusion, forced TFF1 expression in Y79 cells revealed several potential interaction partners in TFF1 signaling. Future functional experiments will be necessary to reveal the mode of interaction between TFF1 and the identified differentially expressed genes.
In order to further proof the observed TFF1 effects, we knocked down TFF1 in RBL30 cells and investigated subsequently effects on proliferation and apoptosis levels. We did not detect opposing effects compared to those observed upon forced TFF1 expression, but in contrast to TFF1 overexpression, TFF1 KD does not influence proliferation levels and KD-mediated apoptosis induction is not caspase-3-dependent in this cell line. As a possible explanation one might hypothesize that cultured RB cells endogenously expressing TFF1 might have developed a compensatory mechanism by which they escape TFF1-induced apoptosis and proliferation control. Hence, downregulation of TFF1 not necessarily leads to enhanced proliferation and reduced apoptosis. The development and progression of RB is based on interactions of different oncogenic events like RB1 alterations and changes in p53 signaling, in which TFF1 could play a synergistic or synthetic lethal part by mediating its tumor suppressive effects. The relationships between different signaling networks involving TFF1 expression in RB need to be investigated in more detail in future studies.
In summary, our findings depict a role of TFF1 in reducing cell growth and tumor formation capacity in vivo as well as promoting caspase-dependent apoptosis through activation of p53 in retinoblastoma cells. Besides, we demonstrated that TFF1 overexpression induces downregulation of miR-18a involved in p53 regulation. Finally, we discovered several differentially expressed genes as potential members of TFF1 signaling in RB. Together, our data strengthen a tumor suppressor function of TFF1 in retinoblastoma cells.
